ATE240934T1 - Wasserhaltiges, kristallines calcium-salz der simvastatin dihydroxy offene säure - Google Patents

Wasserhaltiges, kristallines calcium-salz der simvastatin dihydroxy offene säure

Info

Publication number
ATE240934T1
ATE240934T1 AT00301864T AT00301864T ATE240934T1 AT E240934 T1 ATE240934 T1 AT E240934T1 AT 00301864 T AT00301864 T AT 00301864T AT 00301864 T AT00301864 T AT 00301864T AT E240934 T1 ATE240934 T1 AT E240934T1
Authority
AT
Austria
Prior art keywords
hydrous
calcium salt
crystalline calcium
open acid
dihydroxy open
Prior art date
Application number
AT00301864T
Other languages
English (en)
Inventor
Richard D Tillyer
Paul J Reider
Edward J J Grabowski
Feng Xu
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE240934T1 publication Critical patent/ATE240934T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/30—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with trihydroxylic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/26—All rings being cycloaliphatic the ring system containing ten carbon atoms
    • C07C2602/28—Hydrogenated naphthalenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
AT00301864T 1999-03-08 2000-03-07 Wasserhaltiges, kristallines calcium-salz der simvastatin dihydroxy offene säure ATE240934T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12324799P 1999-03-08 1999-03-08
US26474599A 1999-03-09 1999-03-09
PCT/US2000/002627 WO2000053566A1 (en) 1999-03-08 2000-02-02 Crystalline hydrated dihydroxy open-acid simvastatin calcium salt

Publications (1)

Publication Number Publication Date
ATE240934T1 true ATE240934T1 (de) 2003-06-15

Family

ID=26821372

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00301864T ATE240934T1 (de) 1999-03-08 2000-03-07 Wasserhaltiges, kristallines calcium-salz der simvastatin dihydroxy offene säure

Country Status (16)

Country Link
EP (2) EP1163203A1 (de)
JP (2) JP2002539108A (de)
AR (1) AR022857A1 (de)
AT (1) ATE240934T1 (de)
AU (1) AU764048B2 (de)
CA (1) CA2365869A1 (de)
CO (1) CO5150184A1 (de)
DE (1) DE60002769T9 (de)
DK (1) DK1036783T3 (de)
ES (1) ES2198253T3 (de)
HN (1) HN2000000031A (de)
PE (1) PE20001469A1 (de)
PT (1) PT1036783E (de)
SI (1) SI1036783T1 (de)
SV (1) SV2002000035A (de)
WO (1) WO2000053566A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE44578E1 (en) 2000-04-10 2013-11-05 Teva Pharmaceutical Industries, Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
DK1274401T4 (da) 2000-04-10 2014-09-08 Teva Pharma Stabile farmaceutiske sammensætninger indeholdende 7-substituerede-3,5-dihydroxyheptansyrer eller 7-substituerede-3,5-dihydroxyheptensyrer
CA2421018A1 (en) * 2000-09-06 2002-03-14 Merck & Co., Inc. Dihydroxy open-acid salt of simvastatin
CA2422820A1 (en) * 2000-09-19 2002-03-28 Novimmune S.A. Use of statins (hmg-coa reductase inhibitors) for the preparation of medicament as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent
US6777552B2 (en) 2001-08-16 2004-08-17 Teva Pharmaceutical Industries, Ltd. Processes for preparing calcium salt forms of statins
WO2002057229A1 (en) 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
JP4308021B2 (ja) 2002-03-18 2009-08-05 バイオコン・リミテッド 望ましい粒子サイズのアモルファスＨＭＧ−ＣｏＡレダクターゼ阻害剤
US20030195167A1 (en) * 2002-04-15 2003-10-16 Kowa Co., Ltd. PTX3-gene expression inhibitor
CA2486557A1 (en) * 2002-06-13 2003-12-24 Novartis Ag Calcium salts of indole derived statins
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
US6995277B2 (en) 2003-02-11 2006-02-07 Plus Chemicals, B.V. Process for preparing simvastatin having controlled ranges of simvastatin dimer content
EP1790634A3 (de) 2003-06-18 2007-06-13 Teva Pharmaceutical Industries Ltd. Fluvastatin-natrium im Kristallform und Verfahren zu dessen Herstellung
US7368468B2 (en) 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them
US7368581B2 (en) 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Process for the preparation of fluvastatin sodium crystal from XIV
CA2605331A1 (en) * 2005-04-19 2006-11-02 Eisai R & D Management Co., Ltd. Calcium bis[(2s)-3-[3-[(2s)-3-(4-chloro-2-cyanophenoxy)-2- fluoropropoxy]phenyl]-2-isopropoxypropionate] and intermediate thereof
US7816405B2 (en) 2005-04-19 2010-10-19 Eisai R&D Management Co., Ltd. Calcium bis [(2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl ]-2-isopropoxypropionate] and intermediate thereof
TWI559387B (zh) * 2010-08-27 2016-11-21 恩特葛瑞斯股份有限公司 預防乾燥期間高縱橫比結構崩塌之方法
WO2014036548A1 (en) * 2012-08-31 2014-03-06 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Macromolecular prodrugs for hard tissue and methods of use thereof
GB201704687D0 (en) 2017-03-24 2017-05-10 Wockhardt Uk Ltd Pharmaceutical composition of simvastatin or salt thereof
CN113686991A (zh) * 2021-08-31 2021-11-23 南京西默思博检测技术有限公司 测定人血浆中辛伐他汀、β-羟酸辛伐他汀的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5223415A (en) * 1990-10-15 1993-06-29 Merck & Co., Inc. Biosynthetic production of 7-[1',2',6',7',8',8a'(R)-hexahydro-2'(S),6'(R)-dimethyl-8'(S)-hydroxy-1'(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid (triol acid)

Also Published As

Publication number Publication date
PT1036783E (pt) 2003-08-29
PE20001469A1 (es) 2000-12-18
CA2365869A1 (en) 2000-09-14
DK1036783T3 (da) 2003-06-23
EP1163203A1 (de) 2001-12-19
CO5150184A1 (es) 2002-04-29
AU764048B2 (en) 2003-08-07
DE60002769D1 (de) 2003-06-26
DE60002769T9 (de) 2004-11-04
SV2002000035A (es) 2002-01-15
SI1036783T1 (en) 2003-08-31
HN2000000031A (es) 2001-09-25
WO2000053566A1 (en) 2000-09-14
JP2002539108A (ja) 2002-11-19
ES2198253T3 (es) 2004-02-01
EP1036783B1 (de) 2003-05-21
AU2637000A (en) 2000-09-28
EP1036783A1 (de) 2000-09-20
DE60002769T2 (de) 2004-03-18
JP2000281626A (ja) 2000-10-10
AR022857A1 (es) 2002-09-04

Similar Documents

Publication Publication Date Title
DE60002769D1 (de) Wasserhaltiges, kristallines Calcium-Salz der Simvastatin Dihydroxy offene Säure
DE60004317D1 (de) Salze von Sulfonium-Verbindungen
GB2357759A8 (en) Diaryliodonium salt photolatent acid donors
IS7728A (is) Aðferð til að framleiða kalsíumsalt rósuvastatíns
DE50212273D1 (de) Pharmazeutische salze von 1-phenyl-3-dimethylamino-propan-verbindungen
DE60126611D1 (de) Ditosylatsalze von chinazolinverbindungen
DE60032256D1 (de) Verbesserte sichtbarkeit medizinischer implantate
DE60220128D1 (de) Absorbierbarer Knochenanker
NZ523557A (en) Calcium salt of valsartan
NO20041082L (no) Fremgangsmater for fremstilling av kalsiumsaltformer av statiner
DE69811892D1 (de) Kristalline form von omeprazol-natriumsalz
DE69918445D1 (de) Kalziumsalze enthaltende schweisshemmende zusammensetzungen
NO20055730D0 (no) Forbedret produksjon av rosuvastatin kalsiumsalt
PT1227088E (pt) Base cristalina de citalopram e seu sal cloridrato ou bromidrato
EE200100647A (et) Ühendite uus kasutamine antibakteriaalsete ainetena
ATE273984T1 (de) Selektive kristallisierung von 3-pyridyl-1- hydroxyethyliden-1,1-bisphosphonsäure natrium als hemipentahydrat oder monohydrat
PT1239733E (pt) Combinacoes de substancias activas fungicidas
IS5989A (is) Nýtt kristallað form kalíumsalts (S)-ómeprasóls
HUP0202536A3 (en) Crystals of the sodium salt of pravastatin
NO20020365L (no) Oligonukleotider for inhibiering av ekspresjonen av humant eg5
ATE455754T1 (de) Arylsulfonamid-substituierte hydroxamsäure- derivate
NO20041758L (no) Krystallinsk natriumesalt av telmiseartan og dets anvendelse som angiotensin-antagonist
NO331228B1 (no) Anvendelse av en sammensetning som omfatter et ketotifensalt
DE60107074D1 (de) Kristallin form ii von cabergolin
NO20016151D0 (no) Fremstilling av substituerte piperidin-4-oner

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1036783

Country of ref document: EP

REN Ceased due to non-payment of the annual fee